The Oncologist is committed to helping physicians excel in the constantly changing fields of oncology and hematology through the publication of timely reviews, original studies, and commentaries on important developments.
This case report illustrates the therapeutic opportunities offered through identification of homologous recombination repair deficiency in pancreatic cance
The prognostic value of the ESAS tool is unknown in gastroesophageal cancer. This study examined the association between the ESAS score and overall surviva
The Oncologist is committed to helping physicians excel in the constantly changing fields of oncology and hematology through the publication of timely reviews, original studies,…
The Oncologist is committed to helping physicians excel in the constantly changing fields of oncology and hematology through the publication of timely reviews, original studies,…
This study evaluated the association between insurer (commercial vs Medicaid) and the use of high-priced cancer treatments. Commercially insured and Medica
This commentary explores the language choices that oncology providers make when discussing cancer therapy goals.
This report examines darolutamide tolerability from extended follow-up for both the double-blind and open-label treatment periods of the phase III ARAMIS t
This is the largest study to date to evaluate the clinical impact of different timing and treatment patterns of first-line targeted therapy in patients with…
This study evaluated patient and disease characteristics, treatment, and prognosis of male breast cancer among patients registered with the Complex Oncological
This article reports clinical trial results of a phase II trial assessing the efficacy of rucaparib in patients with high-risk biochemically recurrent nonmetast
